Rice University scientists have achieved the total synthesis of a scarce natural marine product that may become a powerful cancer-fighting agent – the molecule shishijimicin A.
A group led by world-renowned Rice chemist K.C. Nicolaou announced the successful synthesis this month in the Journal of the American Chemical Society.
The complex organic molecule was discovered in a rare sea squirt, Didemnum proliferum, more than a decade ago. Lab tests at the time proved it to be more than 1,000 times as toxic to cancer cells as the anticancer drug taxol (aka paclitaxel), but its scarcity did not provide amounts sufficient for extensive biological studies and clinical trials.
For that, chemists needed to design and develop the many steps required to synthesize the molecule, a specialty for which Nicolaou is well-known. Nicolaou, who joined Rice in 2013, is noted for achieving the first synthesis of taxol as well as the synthesis of the highly cytotoxic compound calicheamicin, which was used in the first antibody-drug conjugate (ADC) for targeted chemotherapy.
Nicolaou said shishijimicin shows just as much potential – and perhaps more – for cancer treatment via “Trojan horse”-style ADCs tuned to target specific types of cancer. “Because it’s so potent, you may only need one or two molecules to get into a cancer cell to do the job,” he said.
Such toxins kill cancer cells by cleaving their DNA or freezing their cytoskeletons to prevent them from replicating, he said.
The path to synthesis took a rapid two years because much of the groundwork had already been set by Nicolaou’s basic work three decades ago in the total synthesis of calicheamicin.
“All the fundamental science for the shishijimicin project was done in the 1990s,” he said. “What we synthesized then was too toxic to be used, but now it has revitalized the whole field because biologists and clinicians can selectively target cancer cells (with ADCs). If we hadn’t done the fundamental science so many years ago, it would have taken us so much longer to come to the same point.”
Nicolaou said his prime concern, in addition to facilitating biology and medicine, is to advance the field of synthetic chemistry. “If we don’t advance it now, we won’t be able to make the complex molecules of the future,” he said. “We have to continue to sharpen the tools of organic synthesis.”
Nicolaou said the next steps for shishijimicin are to streamline its synthesis and add chemical handles so it can be attached to antibodies for delivery to cancer cells. “We’ve established the beachhead with the first total synthesis,” he said. “Now we aim to optimize the process to make it more practical and apply it to synthesize variations of the molecule.”
Then it will be up to partner pharmaceutical companies to develop the compound for eventual clinical trials. They won’t need much, Nicolaou said. “If they have a few hundred milligrams – a fraction of a gram – they can take it to clinical trials, because it’s so potent,” he said. “And now they have hundreds of antibodies selected for different kinds of cancer. My hope is that our molecule will lead to an effective drug for personalized medicine.”
Rice postdoctoral researchers Zhaoyong Lu, James Woods and Te-ik Sohn and graduate student Ruofan Li are co-authors of the paper. Nicolaou is Rice’s Harry C. and Olga K. Wiess Professor of Chemistry.
The Cancer Prevention and Research Institute of Texas and the Welch Foundation supported the research.
Overall survival more than doubles in Phase II clinical trial studying radiation of patients with limited metastatic #lungcancer https://t.co/3Cw0RSFDwI #ASTRO18 #LCSM #endcancer
While being a popular seasonal drink, pumpkin spice lattes can be packed with sugar. Here is a healthier version to try just in time for the cooler temps: https://t.co/7tJjobpnY8. https://t.co/2IZdprjbwp
TAMU Health Sciences@TAMHSC
RT @TAMU: Learn about different cultures from around the world & win prizes at @MSC_FLI's annual Campus Cultural Challenge tomorrow! 🌏🌎🌍 #t…
RT @JoeHermanMD: Great 5k run this morning with colleagues to support the Radiation Oncology Institute! #onemdanderson #radonc @ppisters @S…
When Robert Alvarez was first diagnosed, he didn’t feel comfortable having surgery to remove a tumor in his brain. That changed when he came to MD Anderson and met Dr. Sujit Prabhu: https://t.co/HklSlyqVf4 @MDABrainSpine #btsm #endcancer https://t.co/vFPiOqNEKb
RT @BCMHouston_News: .@bcmhouston's @yoder_alison will present her research into the management of diffuse large B cell lymphoma today at #…
Baby shower help for 50 Veteran mothers at Miami VA hospital https://t.co/gzMBOgxeit via @wsvn
RT @bilalmomhammad: Great to see our pathology colleagues at @utmbhealth doing so well !!! @utmbnews @UTMB_Pathology @UTMBProvost https://t…
Researchers from Baylor College of Medicine, @MethodistHosp and @TexasChildrens receive a Specialized Center of Research grant to expand blood cancer therapy options. https://t.co/IcGckHPSBM #grants #cancer #research
RT @BruceTjadenMD: Here at @UTCVSurgery and @UTHealth, we are carrying out a #randomized #ClinicalTrial to compare #medical management vs #…
Veteran Affairs Office in Des Moines, IA holding coat drive https://t.co/IUDLZBpiZF via @weareiowa5news
RT @MillionHeartsUS: #Stroke risk increases with age, but strokes can (and do) happen at any age. Raise awareness of the importance of stro…
RT @BCMHouston_News: We are pleased to welcome Dr. Alastair Thompson to @bcmhouston! Dr. Thompson will lead #breastcancer surgical oncology…
RT @HRSonline: Sudden #cardiacarrest claims 1 life every 90 secs. A few #SCA risk factors include a previous #heartattack, family history o…
The Dallas, TX VA and Vet Center teams met last week with leadership from the Urban Inter-Tribal Center of Texas to outline how their respective organizations can join forces to effectively reach and serve American Indian and Alaska Native Veterans. https://t.co/EBX1x6cPoV